BPMC - Blueprint Medicines Corporation: An Undervalued Company With Attractive Prospects
Today, we will see why Blueprint Medicines Corporation (BPMC) is an attractive pick in 2020.
Company overview
Founded in 2008 and headquartered in Cambridge, Massachusetts, Blueprint Medicines Corporation went public in 2015. The company is developing precision therapies by leveraging the science of small molecule kinase inhibitors to target genomic drivers in various cancers and rare genetic diseases.
Blueprint Medicines lead asset, avapritinib, is a potent and selective inhibitor of activated KIT and PDGFRA mutant kinases. Ayvakit (avapritinib) has been approved by the FDA for the treatment of GIST (gastrointestinal stromal tumor) harboring